slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
770.000 KRW | -1,28% | -1,41% | +1,32% |
25/04 | Samsung Bioepis krijgt goedkeuring om auto-immuunbehandeling in Europa op de markt te brengen | MT |
25/04 | Samsung Biologics boekt meer winst en omzet in Q1 | MT |
Omzet 2024 * | 4.263 mld. 3,1 mld. 2,9 mld. | Omzet 2025 * | 4.915 mld. 3,57 mld. 3,34 mld. | Marktkapitalisatie | 54.804 mld. 39,84 mld. 37,27 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 976 mld. 710 mln. 664 mln. | Nettowinst (verlies) 2025 * | 1.177 mld. 856 mln. 800 mln. | EV/omzet 2024 * | 12,4 x |
Nettoliquiditeiten 2024 * | 2.085 mld. 1,52 mld. 1,42 mld. | Nettoliquiditeiten 2025 * | 2.961 mld. 2,15 mld. 2,01 mld. | EV/omzet 2025 * | 10,5 x |
K/w-verhouding 2024 * |
56,2
x | K/w-verhouding 2025 * |
47,8
x | Werknemers | 4.284 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 25,25% |
1 dag | -1,28% | ||
1 week | -1,41% | ||
Lopende maand | -7,34% | ||
1 maand | -7,00% | ||
3 maanden | -0,39% | ||
6 maanden | +5,62% | ||
Lopend jaar | +1,32% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Chongbo Rim
CEO | Chief Executive Officer | 62 | 01-01-18 |
Doyoung Heo
DFI | Director of Finance/CFO | - | - |
Tae-Han Kim
CHM | Chairman | 66 | 21-04-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chang-Woo Lee
BRD | Director/Board Member | 70 | - |
Tae-Han Kim
CHM | Chairman | 66 | 21-04-11 |
Seok-Woo Jung
BRD | Director/Board Member | 62 | - |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
4.63% | 2 M€ | -14,14% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 770.000 | -1,28% | 82 298 |
25-04-24 | 780.000 | -1,27% | 68 732 |
24-04-24 | 790.000 | -0,13% | 48 667 |
23-04-24 | 791.000 | -1,37% | 44 112 |
22-04-24 | 802.000 | +2,69% | 59 922 |
slotkoers Korea S.E., 26 april 2024
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,32% | 39,82 mld. | |
-4,66% | 86,13 mld. | |
-19,27% | 30,42 mld. | |
+57,86% | 25,23 mld. | |
-17,69% | 11,6 mld. | |
-43,00% | 11,51 mld. | |
-9,14% | 11,95 mld. | |
+5,24% | 8,71 mld. | |
-8,42% | 8,12 mld. | |
+2,29% | 7,72 mld. |